Afternoon update
Biotech and semiconductors set the tone on November 16.


Biotech and semiconductors set the tone on November 16. The S&P 500 fell 1.72% to 7431.40 and the Nasdaq dropped 2.25% to 24570.74.
- $SMMT fell 16.89% to $11.76, a $9.46B market cap. The FDA issued a complete response letter on the application for ivonescimab plus chemotherapy in lung cancer after the late-stage study missed statistical significance for overall survival.
- The decision sets a regulatory precedent with read-through risk for similar candidates at Bristol-Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
- Micron fell 6.82% to $725.24 and AMD 5.09% to $506.88. AI-linked stocks are de-risking ahead of Nvidia's Tuesday earnings and Anthropic's anticipated Thursday IPO, following last week's resignation of Nvidia CEO Jensen Huang.
- The semiconductor basket finished 0 for 11, down 4.63%, with Intel off 7.31%. SMH fell 4.73%, and the SOX stalled near its 200-day moving average after last week's rally failed.
- Consumer staples led at +0.64%, with 9 of 10 names higher and Colgate up 2.06%. XLP gained 0.42% while XLK fell 2.90%.
The defensive rotation reflects investors reducing AI exposure ahead of a pivotal week. Nvidia's report on Tuesday is the next test for the group.
Not financial advice. For informational and educational purposes only.
Originally published on the Position Tracker Substack.
Read on Substack ↗